Project description:The overall goal of this study was to characterize bone marrow cells based on their transcriptome, surface protein expression and BCR- and TCR VDJ-profile for accurate identification of clinically relevant cell states. This submission includes pediatric B-cell acute lymphoblastic leukemia samples. This project has received funding from the European Union Horizon 2020 research and innovation programme under grant agreement No 824110 (EASI-Genomics)
Project description:The overall goal of this study was to characterize bone marrow cells based on their transcriptome, surface protein expression and BCR-VDJ-profile for accurate identification of clinically relevant cell states. This submission includes B-cell acute lymphoblastic (pre-)leukemia samples from mice. This project has received funding from ERA perMed JTC2018 under the title „Genomics-based tools for personalized treatment to reduce chemotherapy burden in paediatric cancer” (Acronym “GEPARD”)
Project description:The overall goal of this study was to characterize bone marrow cells based on their transcriptome. This submission includes preleukemic samples (B-cell acute lymphoblastic leukemia) from 6 mice. This project has received funding from ERA perMed JTC2018 under the title „Genomics-based tools for personalized treatment to reduce chemotherapy burden in paediatric cancer” (Acronym “GEPARD”)
Project description:The bone marrow microenvironment of leukemia plays a key role in leukemia progression, but its molecular complexity in pre-B acute lymphoblastic leukemia (B-ALL), the most common cancer in children, remains poorly understood. Here we use single-cell RNA sequencing to characterise the bone marrow microenvironment during B-ALL progression.
Project description:The overall goal of this study was to profile pediatric acute lymphoblastic leukemia bone marrow tissue based on their transcriptome to characterize clinically relevant subtypes. This project has received funding from Cancer Society of Finland, Jane and Aatos Erkko Foundation and ERAPerMed (Reference Number: ERAPERMED2018-209) under the ERA-NET Cofund scheme of the Horizon 2020 Research and Innovation Framework Programme of the European Commission Research Directorate-General Grant Agreement No. 779282.